Key result
Serum Ephrin-A1 demonstrated diagnostic potential for colorectal cancer with an AUC of 0.709, and levels were significantly higher in patients with colorectal cancer compared to healthy controls.
Why the study?
Colorectal cancer has high incidence and mortality, and serum biomarker analysis is attractive for diagnosis due to low cost, repeatability, and quantification.
Does serum Ephrin-A1 accurately diagnose colorectal cancer in newly diagnosed patients compared to healthy controls?
Case-Control (n=466)
Yes
Does serum Ephrin-A1 accurately diagnose colorectal cancer in newly diagnosed patients compared to healthy controls?
Effect estimate: AUC 0.709 (95% CI 0.644-0.775)
Serum Ephrin-A1 might serve as a potential biomarker for the diagnosis of colorectal cancer, and its combination with CEA shows good early diagnostic efficacy.
Serum Ephrin-A1 shows limited diagnostic performance in case-control data; leaves open prospective validation as a CRC biomarker.
Colorectal cancer (CRC) is one of the most common malignant tumors worldwide, with a high incidence rate and mortality. The analysis of serum biomarkers for colorectal cancer diagnosis has attracted more and more attention because of its low cost, repeatability, and quantification. This study was aimed to evaluate the diagnostic performance of serum Ephrin-A1 in patients with CRC. We retrospectively analyzed CRC cases in a test cohort (121 patients and 108 controls) and validated them in a validation cohort (119 patients and 118 controls). The concentration of Ephrin-A1 in serum was detected by Enzyme-linked immunosorbent assay (ELISA) and the diagnostic performance of serum Ephrin-A1 was evaluated by receiver operating characteristic (ROC) analysis. In the test cohort, serum Ephrin-A1 levels in patients with all-stage CRC and early-stage CRC were significantly higher than those in healthy controls. The area under the ROC curve (AUC), sensitivity and specificity of all-stage CRC and early-stage CRC were 0.709 (95% CI 0.644-0.775) and 0.660 (95% CI 0.530-0.790), 48.76% and 45.00%, 81.48% and 81.48%, respectively. Similar results were observed in the validation cohort. Serum Ephrin-A1 might be served as a potential biomarker in the diagnosis of CRC.
No takes yet. Share an insight, caveat, or question.
Su et al. (2024) conducted a case-control in Colorectal cancer (n=466). Serum Ephrin-A1 vs. Healthy controls was evaluated on Diagnostic performance (AUC) for all-stage colorectal cancer in the test cohort (AUC 0.709, 95% CI 0.644-0.775). Serum Ephrin-A1 demonstrated diagnostic potential for colorectal cancer with an AUC of 0.709, and levels were significantly higher in patients with colorectal cancer compared to healthy controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: